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ABSTRACT 
A fundamental problem in the field of management of technology is how firms develop and 
sustain disruptive technologies for competitive advantage in markets. The vast literature has 
analyzed several characteristics of disruptive innovations. However, the determinants are 
hardly known. The study here seems to show, in a market with high intensity of R&D 
investments (anticancer drugs), that the emergence of disruptive technologies can be driven 
by the coevolution of consequential problems and their solution in R&D labs of firms. In 
general, incumbent and entrant firms have a strong incentive to find innovative solutions to 
unsolved, consequential and new problems in order to achieve and sustain the prospect of a 
(temporary) profit monopoly and competitive advantage in markets with technological 
dynamisms. Overall, then this study shows one of the general sources of disruptive 
technologies that seems to support industrial and corporate change in a Schumpeterian world 
of innovation-based competition. 
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Disruptive technologies and competitive advantage of firms in dynamic markets 
MARIO COCCIA 
1. OVERVIEW OF THE PROBLEM  
This article has two goals. The first is to explain how firms develop and sustain disruptive 
innovations. The second is to show the strategic change1 of R&D management for supporting 
disruptive technologies and competitive advantage in drug discovery industry.  
Management studies have a considerable interest in studying disruptive innovations2 because 
they can explain how firms achieve and sustain competitive advantage in markets (Teece et al., 
1997; Chesbrough and Rosenbloom, 2002; Gilbert and Bower, 2002; Danneels, 2006; Jenkins, 
2010; King and Baatartogtokh, 2015; Garud et al., 2015; cf., Coccia, 2005a, 2005b, 2006)3. The 
research field of disruptive innovations analyses different characteristics, such as the meaning of 
disruptive technology (Christensen et al., 2015; Tellis, 2006), technological challenges of in-
cumbent firms (Christensen, 1997, 2006; Danneels, 2004; Hill and Rothaermel, 2003; Ansari et 
al., 2016; Wessel and Christensen, 2012), market of technology (Arora et al., 2001), leadership 
effects on innovative activity of firms (Ryan and Tipu, 2013), organizational networks (Garud et 
al., 2002), etc.  
However, the sources of disruptive innovations among different industries are hardly known. 
In this research domain, critical research questions for management of technology are: what is a 
vital driver of disruptive innovations in firms? And how R&D management support the devel-
opment of disruptive technologies in industries with high intensity of research investments? 
With respect to these questions, the study here endeavours to explain one of contributing factors 
that supports disruptive technologies of firms operating into the market of new anticancer treat-
ments. The findings can provide an integrative approach within current theoretical framework of 
disruptive technologies that can advance our understanding of the sources of disruptive innova-
tion and related R&D management implications. In order to position this study in existing ap-
proaches, the paper begins by reviewing some accepted frameworks for analyzing the sources of 
disruptive innovation in drug discovery industry. 
                                                     
1 Gioia and Chittipeddi, 1991.  
2  Disruptive technology is a concept similar to radical innovations, technological paradigms, technologi-
cal regimes or path-breaking technologies analyzed in economics of innovation (Freeman and Soete, 
1987, p. 56ff; Dosi, 1988; Nelson and Winter, 1982). The study here uses these terms in interchangea-
ble way.  
3 See also Coccia and Wang, 2016; Coccia, 2009c, 2015c, 2017; and for environments and science that 
support innovation cf., Coccia, 2005c, 2008c, 2009d, 2010, 2011, 2010a, 2010b, 2010c, 2010d, 2013a, 
2014c, 2014d, 2014e, 2015a, Coccia and Bozeman, 2016: Coccia and Wang, 2016; Coccia and Rolfo, 
2000, 2002; Rolfo and Coccia, 2005.  
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2. THEORETICAL FRAMEWORK AND WORKING HYPOTHESES 
Christensen et al. (2015) argue that disruptive innovations are generated by small firms with 
fewer resources that successfully challenge established incumbent businesses. In particular, in-
cumbents focus on improving their products and services for markets (usually most profitable), 
whereas entrants endeavour to develop disruptive technologies in some market segments, deliv-
ering the market performance that incumbents’ mainstream customers require (Christensen et 
al., 2015; Christensen, 1997; Calabrese et al., 2005). Firms, generating path-breaking innova-
tions, grow more rapidly than other ones (Tushman and Anderson, 1986, p. 439). Christensen’s 
(1997) approach also argues that disruptive innovations generate significant shifts in markets 
(cf., Henderson, 2006). In general, the technological and market shifts embody competence-
destroying and competence-enhancing because some firms can either destroy or enhance the 
competence existing in an industry (cf., Hill and Rothaermel, 2003; Tushman and Anderson, 
1986). In this context, management studies focus on the concept of ambidexterity: the organiza-
tional behaviour to simultaneously engage in exploratory and exploitative activities that support 
both incremental and radical innovations. As a matter of fact, new firms tend to generate com-
petence-destroying discontinuities that increase the environmental turbulence, whereas incum-
bents focus mainly on competence-enhancing discontinuities that decrease this turbulence. 
Competence-destroying and competence-enhancing can be due to an ambidexterity behaviour of 
some firms that simultaneously engage in exploratory and exploitative activities to support in-
cremental and radical innovations (O’Reilly and Tushman, 2004, 2008; Lin and McDonough 
III, 2014; Durisin and Todorova, 2012)4. Some studies argue that the ability of incumbents to 
develop and to market disruptive innovations is due to their specific ambidexterity (Danneels, 
2006; cf., Henderson, 2006). In this R&D management, a main role is also played by “forward-
looking executives seeking to pioneer radical or disruptive innovations while pursuing incre-
mental gains” (O’Reilly III and Tushman, 2004, p. 76). Disruptive innovation and its develop-
ment are also due to organizational learning, which is a fundamental strategic process for com-
petitive advantage of firms (Vera and Crossan, 2004). Moreover, managers with strategic lead-
ership within firms play a vital for innovation processes because they inspire others with their 
vision, create excitement in groups and provide incentives for achieving goals in competitive 
environments (Bass and Avolio, 1990).  
In general, disruptive innovations generate main effects both for consumers and producers in 
markets and society during the process of diffusion (Markides, 2006, pp.22-23; Markides and 
Geroski, 2005; O'Neill et al., 1998). In general, disruptive innovations change habits of con-
sumers in markets and undermine the competences and complementary assets of existing pro-
ducers. Calvano (2007) argues that: “we highlight the role of destruction rather than creation in 
driving innovative activity. The formal analysis shows that destructive creation unambiguously 
leads to higher profits whatever the innovation cost” (cf., Tripsas, 1997). In particular, disrup-
tive innovations disturb the business models of incumbents that have to counter mobilize re-
sources to sustain their competitive advantage in the presence of market change (Garud et al., 
2002; Markman and Waldron, 2014). Moreover, disruptive innovation speed is also important to 
a firm's creating and sustaining competitive advantage amidst rapidly changing business envi-
ronments. Kessler and Chakrabarti (1996, p. 1143) argue that the “innovation speed (a) is most 
appropriate in environments characterized by competitive intensity, technological and market 
dynamism, and low regulatory restrictiveness; (b) can be positively or negatively affected by 
strategic-orientation factors and organizational-capability factors; and (c) has an influence on 
development costs, product quality, and ultimately project success”. These characteristics of 
new radical technological regimes in markets require that incumbents undertake specific R&D 
investments and strategies (Christensen and Raynor, 2003). Although the literature has focused 
on in-house R&D investments (e.g., Chesbrough and Rosenbloom, 2002; Henderson and Clark, 
1990; Tripsas and Gavetti, 2000), incumbents increasingly build research alliances to increase 
the access to external knowledge from new firms and/or research organizations (i.e., universi-
                                                     
4 cf., Coccia, 2016; 2014b; Coccia and Wang, 2015 
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ties, research institutes; cf., Nicholls-Nixon and Woo, 2003; Coccia, 2014b; Cariola and Coccia, 
2004).  
A sector with several disruptive innovations is the pharmaceutical industry because of revo-
lution of molecular biology and nanotechnology in diagnostics and therapeutics (Coccia, 2012, 
2012b, 2012c, 2013, 2014, 2014a, 2015; Coccia et al., 2012). In this specific industry, gene 
therapy is a new technological regime emerged during the 1990s that represents a disruptive 
technology directed to personalized medicine and treatments with higher effectiveness for pa-
tients (Wilson, 2012). Kapoor and Klueter (2015) explore some new therapeutic approaches and 
show that the commercialization of both monoclonal antibodies and gene therapy required that 
incumbent firms had access to specialized complementary assets such as capabilities in clinical 
development, relationships with health care service providers and sales teams (cf., Gershon, 
1998). Kapoor and Klueter (2015) also argue that incumbents tend to not invest in disruptive 
technological regimes and maintain a competence-enhancing approach. However, current wave 
of research alliances and acquisitions in this industry may help incumbents to overcome this 
“inertia” both in the initial stage of research and in the later stage of development. Other studies 
show that R&D investments of innovative enterprises in pharmaceutical industry are directed 
towards both internal research units and strategic alliances to accelerate the drug discovery pro-
cess (Coccia, 2005; 2007; 2008a; 2008b; 2009; 2012d; 2014b, 2016, 2016a, 2016b; cf. Coccia et 
al., 2012).  
Theoretical framework of disruptive technologies suffers of some limitations such as the 
ambiguity in the definition of disruptive innovations that considers technologies but also prod-
ucts and business models (cf., Tellis, 2006; Christensen and Raynor, 2003). Strictly speaking, a 
disruptive technological innovation is fundamentally a different phenomenon from a disruptive 
business-model innovation. Disruptive innovations arise in different ways, have different com-
petitive effects, and require different responses from organizational behavior of incumbents and 
entrants (Markides, 2006, p. 19). These factors are due to a variation in the sources of innova-
tion such as in some industries, innovation users develop innovation, in others most innovations 
are due to suppliers of innovation-related components and product manufactures (von Hippel, 
1988). This variation in the sources of innovation is related to “functional source of innovation 
….functional relationship through which they [firms and individuals] derive benefit from a giv-
en product, process, or service innovation” (von Hippel, 1988, p. 3, original italics). The under-
standing of determinants of such variation is important to predict and manage major and minor 
innovation processes of firms. A vital factor in the development of innovations is also played by 
the coevolution of technical and institutional events (Van de Ven and Garud, 1994). In the con-
text of basic sources of innovative activities, Usher (1954) proposed a theoretical framework, 
based on Gestalt psychology, with four main concepts that can explain the emergence and evo-
lution of new technology: 
1. Perception of the problem: an incomplete pattern in need of resolution is recognized. 
2. Setting stage: assimilation of data related to the problem. 
3. Act of insight: a mental act finds a solution to the problem. 
4. Critical revision: overall exploration and revision of the problem and improvements 
by means of new acts of insight.  
This theory focuses on accumulation of knowledge and acts of insight that are basic to solve 
technological problems and develop new technology. Alexander (1964, pp. 15-16) also showed 
the role of problem solving for new processes of design: “Every design problem begins with an 
effort to achieve fitness between two entities: the form in question and its context. The form is 
the solution to the problem; the context defines the problem. In other words, when we speak of 
design, the real objet of discussion is not the form alone, but the ensemble comprising the form 
and its context” (cf., Kruger and Cross, 2006; Möhrle and Pannenbäcker, 1997). Dosi (1988, 
original emphasis) also argued that technological paradigm in markets can be due to solutions of 
selected technological problems (cf., Coccia, 2014b; 2016). The theoretical linkage between 
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problems and their solutions is also emphasized by Popper (1959) in the philosophical analysis 
of the process of scientific discovery (cf., Lai, 1989, p. 363). 
Although scholars recognize that there are different and contextual determinants of path-
breaking innovations, in management there has not been a substantial effort to define a common 
factor, a prime mover, among major and minor innovations (cf., Dosi, 1988; Christensen, 1997; 
Christensen et al., 2015; Coccia, 2012)5. In fact, a theory of innovation is supposed to explain 
the determinants of minor and major technological breakthroughs in markets, such as the drivers 
of disruptive innovations. The theoretical frameworks just discussed suggest a general relation 
between relevant problems and emergence of disruptive technologies that deserve to be ex-
plored.  
Suppose that: 
 disruptive technologies are major innovations that make prior technical knowledge obsolete 
and sustain industrial and corporate change.  
 there exists, at a given time, a relevant problem/need unresolved for consumers in markets.  
 
The working hypotheses of the study here are:  
HPθ : Relevant problems/needs and their solutions generate disruptive innovations, ceteris pa-
ribus.  
HPσ : Development of disruptive technologies needs a division of scientific labour in the R&D 
function, ceteris paribus.  
 
The principal HPθ, called problem-driven disruptive innovation, is the core of the causal 
model in Figure 1. Unlike the theoretical framework of disruptive innovation (Christensen, 
1997), the model here shows that, in a market with high intensity of R&D investments, the 
emergence of disruptive innovation A can be driven by the coevolution of relevant problems 
and their solution in R&D labs of incumbent firms φ, but a small (entrant) firm ε can generate a 
major technological breakthrough B by solving a consequential problem of previous (disruptive) 
technology. This new technological shift triggers a competitive reaction of incumbent φ with a 
new major innovation B’ (similar to B).  
 
Figure 1: Disruptive innovation driven by consequential problems in an industry with high in-
tensity of R&D investments. 
  
 
                                                     
5 Cf. also Cavallo et al., 2014, 2014a, 2015; Coccia, 2004.  
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3. METHODS 
This study hypothesizes that relevant problems and their solutions in R&D labs of firms hav-
ing a division of scientific labour can support the emergence and development of disruptive 
technologies, ceteris paribus (fig.1). The methodology to support the hypotheses is an inductive 
study of case study research to explain one of causing factors of disruptive innovations and 
R&D management implications (Eisenhardt, 1989; Eisenhardt and Graebner, 2007). In particu-
lar, the study here focuses on new target therapies for lung cancer that are generating a para-
digm shift in anticancer treatments because of new biopharmaceuticals and small-molecules 
originated by a convergence of genetics, genomics and proteomics (cf. Coccia, 2012c; 2012e; 
2012f, 2015b, 2016a, 2016b; cf., Coccia, 2012g).  
The study analyzes three multinational health-care enterprises (incumbents) and a new small 
firm (entrant) that produce this specific type of disruptive innovations in the market of anti-
cancer treatments. In particular, incumbents in this specific market are:  
• AstraZeneca (AZ) is a an British–Swedish research-based biopharmaceutical company 
based on Astra AB formed in 1913 (Sweden) and British Zeneca Group formed in 1993; 
Astra AB merged with Zeneca group to form AstraZeneca in 1999.  
• Roche is a Swiss multinational health-care company founded in 1896. 
• Boehringer Ingelheim (Germany) founded in 1885. It is one of leading pharmaceutical 
companies worldwide. 
The entrant firm is: 
• Clovis oncology, a small US pharmaceutical company founded in 2009. 
Firstly, the study analyzes shortly the organizational structure of these firms (revenue, oper-
ating income, total assets, number of employees and R&D process) considering last data availa-
ble from annual reports. Secondly, the study focuses on innovation process that has driven the 
development of disruptive innovations for lung cancer treatments and the underlying R&D 
management. The period under study is from 2009 onwards.  
Expected evidence of the inductive study here is to instantiate the hypotheses that disruptive 
innovations are mainly driven by coevolution of relevant problems and their solution within 
R&D laboratories with a division of scientific labour. Findings may also have the potential to 
clarify one of the general and basic sources of disruptive technologies across several industries 
in regimes of rapid change.  
4. INDUCTIVE ANALYSIS TO SUPPORT THE HYPOTHESES 
 Human and economic resources, and R&D strategy to support disruptive innovations. 
AstraZeneca (AZ) 
AstraZeneca is a company that has a net income of US$2.825 billion (AstraZeneca, 2015b), 
total assets for US$60.12 billion (Forbes, 2016) and total number of employees for about 50,000 
(AstraZeneca, 2015). The human and economic resources invested in R&D by AstraZeneca are 
about 15,000 units of personnel and over US$4 billion in eight countries (AstraZeneca, 2015). 
The discovery phase in AZ is about 4 years to find potential drugs through laboratory re-
search; the development phase is 7 years based on: phase I (small group of volunteers to under-
stand potential new drugs); phase II (small group of patients to evaluate the effectiveness of the 
medicine); phase III (large group of patients to gather information about effectiveness and safe-
ty) and regulatory submission to seek approval from regulatory authorities; post lunch deliver-
ing to patients is about 10 years. In short, the length of time of the drug discovery process is 
roughly 20 years (AstraZeneca, 2015a). AstraZeneca (AZ) to be continually at the forefront of 
ground-breaking research into human disease has strategic partnerships with organizations to 
complement in-house technological and scientific capabilities. In particular, AZ builds and rein-
forces the scientific capabilities by strategic alliances with external sources of innovation: part-
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nership with academic institutions, bio-techs and other pharmaceutical companies to share 
skills, knowledge and resources through all phases of the R&D process described above. In ad-
dition, the acquisition of the biotechnology firm MedImmune has improved and enlarged the 
R&D function and technological capabilities (AstraZeneca, 2015, 2015a).  
 
Roche 
Roche is a Swiss multinational health-care company that has an operating income of US$ 
13,852 billion, profit of US$ 9,374 billion, total assets of US$ 46,475 billion and number of 
employees of 88,509 (Roche, 2015a). The resources in R&D are based on over 18,000 research-
ers worldwide and about US$10.6 billion of investments. R&D processes in Roche are repre-
sented by research and early development (target selection; lead generation); clinical develop-
ment; commercialization. New products need over 12 years from first discovery. In general, the 
value chain of the R&D process to support one innovative drug is driven by roughly: 
US$1,058,249,692.118 of R&D Investment; 7,000,874 Hours of work; 6587 Experiments; 423 
Researchers (Roche, 2015). Moreover, Roche, in order to support the drug discoveries in con-
verging genetics, genomics and proteomics, is also an active partnering organization with more 
than 30% of research projects in the pipeline that have been carried out with strategic alliances. 
Roche has a dynamic role to transform key partnerships into strategic alliances. R&D function 
is also reinforced by academic partnerships that seek to propel progress in translational medi-
cine and by the subsidiary Genentech in biotechnology (Roche, 2015).  
 
Boehringer Ingelheim (Germany) 
The Boehringer Ingelheim group has an operating income of US$ 2,259,932,251, total assets 
of US$ 21,173,123,292.01 and number of employees of 47,744. The R&D human resources are 
more than 7000 highly qualified people (Boehringer-Ingelheim, 2015).  
The drug discovery process is based on the following steps: research (target identification 
and validation; assay development; lead identification; lead optimization; pre-development); 
development (preclinical development, clinical research); registration (regulatory approval); and 
life cycle management. From initial discovery to a marketable medicine is a long process requir-
ing about 12–15 years and an investment of about US$1 billion (Boehringer-Ingelheim, 2015). 
Boehringer Ingelheim also supports the in-house R&D activity with several partnerships with 
academic institutions, start-up companies and biotechnological enterprises. New alliances have 
formed with leading companies in biotechnology, such as Abbott Laboratories, Glaxo Well-
come, Pfizer and Eli Lilly. A strategic acquisition is the micro-technology company STEAG 
microParts GmbH. These strong alliance management functions at Boehringer Ingelheim ensure 
high-level commitment to successful execution of partnerships directed to innovative products 
(Boehringer-Ingelheim, 2015).  
 
 Mortality of lung cancer: a relevant problem as determinant of new disruptive innovations.  
Lung cancer is the most common cause of death from cancer worldwide with the highest 
mortality: 19.7 % in age-standardized rate (Mortality ASR W per 100,000 person per year is the 
rate that a population would have if it had a standard age structure. Standardization is necessary 
when comparing several populations that differ with respect to age because age has a powerful 
influence on the risk of cancer, GLOBOCAN, 2012, 2012a). Lung cancer can be either small 
cell lung cancer or non-small cell lung cancer (NSCLC), with the latter representing about 80-
90% of cases (Coccia, 2012a, 2014). Current anticancer treatments for advanced non-small cell 
lung cancer (NSCLC) are mainly based on chemotherapy agents (such as cisplatin and gemcita-
bine; carboplatin and paclitaxel, and so on). However, this technology has low efficacy for treat-
ing lung cancer since the mortality rate is still high (cf. Ferlay et al., 2013).  
Public and private R&D investments have generated scientific advances in Genetics (the 
study of the molecular structure and function of genes in the context of a cell or organism), Ge-
nomics (a discipline in genetics that studies the genomes of organisms and determines the entire  
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Figure 2. The domain of disruptive technologies for anticancer treatments 
 
 
DNA sequence of organisms and fine-scale genetic mapping efforts) and proteomics (the sys-
tematic analysis of protein profiles of tissues and parallels the related field of genomics; Coccia, 
2012c).  
In particular, studies in molecular biology have shown that cancer cells display self-
sufficiency of growth signals through the accumulation of genetic and epigenetic changes (e.g., 
Epidermal Growth Factor: EGF). The EGF acts by binding with high affinity to the Epidermal 
Growth Factor Receptor (EGF-R) on the cell surface and by stimulating the intrinsic protein-
tyrosine kinase activity of the receptor, which ultimately leads to cancer cell proliferation (Coc-
cia, 2012a). In order to solve this problem, firms -in this innovation-based market- have a pri-
mary incentive to find innovative solutions (e.g., new anticancer drugs) in order to achieve and 
sustain the prospect of a (temporary) profit monopoly (cf., Madsen and Leiblein, 2015). In par-
ticular, the convergence of genetics, genomics and proteomics (Figure 2) has laid the founda-
tions for solution of the problem of lung cancer by developing disruptive technological innova-
tions of target therapies: “drugs or other substances that block the growth and spread of cancer 
by interfering with specific molecules involved in tumor growth and progression” (as defined by 
National Cancer Institute, 2015; Coccia, 2012).  
 
 Incumbent firms and disruptive innovations in anticancer treatments: target therapies for 
lung cancer.  
Incumbent firms in target therapies for lung cancer are three: AstraZeneca (AZ, Sweden-
England), Roche (Switzerland) and Boehringer Ingelheim (Germany). In order to solve the 
problem just mentioned above, R&D labs have generated two main radical innovations to treat 
NSCLC are: Iressa® (based on the blocking agent Gefitinib) by AstraZeneca Company and 
Tarceva® (based on the blocking agent Erlotinib) commercialized by the Roche. These path-
breaking anticancer drugs are generating a revolution in therapeutic treatments of NSCLC with 
EGF-R because they block specific enzymes and growth factor receptors involved in cancer cell 
proliferation (Mitsudomi, 2010, pp. 101-102; Laack et al., 2010). Boehringer-Ingelheim com-
pany (Germany), to solve the problems mentioned above and angiogenesis (growth of blood 
vessels feeding tumors), has also generated innovative target therapies for lung (and other) can-
cer, commercialized roughly from 2014 onwards, based on multi-inhibitor blocking agents such 
as nintedanib (triple angiokinase inhibitor) and afatinib dimaleate –commercial name Gilotrif.  
 
 Consequential problems for technological development of new disruptive technologies.  
Although these disruptive innovations, the incidence and mortality of lung cancer have still 
high rates (GLOBOCAN, 2012, 2012a). Studies in the biology of the cancer show that it can 
become resistant to these new drugs (cf. Lovly et al., 2015). In particular, approximately 60 per-
cent of patients typically relapse within 1–3 years of treatment because of drug resistance to tar-
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get therapies described above. In particular, drug resistance of lung cancer is due to the emer-
gence of a consequential problem: a secondary mutation (T790M) that generates a progression 
of the cancer with several metastases and, as a consequence, high mortality within five years 
(Coccia, 2012a). 
 Entrant firm to solve the consequential problem with new a disruptive technology.  
Clovis Oncology is a small pharmaceutical company, which is generating innovative prod-
ucts for new treatments in oncology. Clovis was founded in 2009 and is headquartered in Boul-
der, Colorado. The company has a market capital of $1.26 billion. The current generation of tar-
get therapy for lung cancer by AZ, Roche and Boehringer-Ingelheim companies is designed to 
target wild type EGFR but this cancer can growth because of new mutations as said above. This 
small pharmaceutical firm, Clovis oncology, has generated a new disruptive innovation to treat 
EGFR-mutant lung cancer. This target therapy, called Rociletinib, is a novel, oral, targeted co-
valent (irreversible) inhibitor to selectively target both the initial activating EGFR mutations 
and the T790M resistance mutation, with an improved toxicity profile (Clovis Oncology, 2015; 
2014). The intensive competition in this drug discovery industry with rapid change has induced 
the biopharmaceutical company AstraZeneca (2015; 2015a) to react by developing a similar an-
ticancer drug. This new path-breaking innovation for mutated EGFR lung cancers is called Ta-
grisso™ (AZD9291) and was approved by US Food and Drug Administration in 2015 (Astra-
Zeneca, 2016). 
Overall, this case study described above seems in general to be consistent with the hypothe-
sis θ of problem-driven innovation that the emergence of disruptive technologies can be ex-
plained by a coevolution of consequential problems and problem-solving activity in R&D labs 
of firms, ceteris paribus. In fact, both incumbent and entrant firms, in innovation-based mar-
kets—as in the drug-discovery industry—have the chief incentive to find innovative solu-
tions/products for unsolved problems in order to achieve and sustain the prospective goal of a 
(temporary) monopoly of profits. The hypothesis of Problem-Driven innovation can explain one 
of the driving forces of disruptive innovations. In addition, this conceptual framework has also 
the potential to explain the general source of several major innovations that support the indus-
trial and corporate change. 
Figure 3 synthetizes the argument here showing that the sources of disruptive innovations in 
this specific pharmaceutical markets are due the interaction between consequential problems 
and their solutions in R&D labs of incumbents and entrant firm.  
 
Figure 3: Drivers of disruptive technologies and competition incumbent-entrant in drug discov-
ery industry for lung cancer  
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Figure 4: Network of R&D function of incumbent firms to support disruptive technologies in 
drug discovery industry.  
 
 
 
Considering the source of disruptive innovations analyzed above, it has consequences for the 
organization of R&D. Von Hippel (1988, p. 9) argued that firms organize R&D departments 
that are capable to develop entirely new product development in-house. However, markets in 
rapid change, such as in drug discovery industry, demand new structures of R&D to reinforce 
the integrative capabilities, collective and cumulative learning between in-house R&D and ex-
ternal sources of innovation (cf., Henderson, 1994). As described above, R&D strategy of in-
cumbent firms is to create strategic alliances with emerging firms of biotechnology for a divi-
sion of scientific labour directed to reinforce and accelerate drug discovery process. This R&D 
management organizes the R&D labs with a network structure based on strategic alliances for 
supporting the discovery process of disruptive innovations (figure 4). This inductive analysis is 
consistent with the hypothesis σ.  
Overall, then, this study suggests a model that explains one of driving forces of the origin 
and development of radical-incremental innovations in competitive markets, with a theoretical 
linkage between emergence of relevant-consequential problems and their solution (i.e., coevolu-
tion of innovation with the evolution of consequential problems). One of the primary contribu-
tions of this article for both scholars and managers is the strategic role in organizations of an ef-
ficient and rapid problem-solving activity. In fact, technical competence and problem-solving 
activity are crucial for developing several innovations since they translate environmental and 
organizational inputs into valuable new products and processes (cf. Atuahene-Gima and Wei, 
2011, pp. 81-82) 
5. DISCUSSION AND GENERALIZATION 
The theoretical framework of disruptive technologies does not explain the drivers of these 
path-breaking technologies (cf., Christensen, 1997). The study here endeavours to clarify, 
whenever possible, one of driving forces of disruptive innovations in drug discovery industry. 
The evidence, based on a case study research in lung cancer treatments, is consistent with the 
hypothesis that disruptive technologies are driven by the coevolution of relevant problems and 
their solutions in a context of scientific division of labor with a network R&D organization. In 
particular, findings here suggest a theoretical linkage between relevant-consequential problems 
and their solution that supports the emergence of disruptive technologies. Main R&D manage-
ment implications are the strategic role of efficient and rapid problem-solving R&D labs of 
firms in markets with rapid change. This analysis of underlying determinants of disruptive in-
novations of anticancer drugs is a complex task but it is very important to understand some gen-
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eral driving forces of technological change in markets (Gelijns and Rosenberg, 1994, p. 30ff; 
1995; Rosenberg et al., 1995; Coccia, 2012).  
In general, firms have goals, such as achieve and sustain competitive advantage (Teece et al., 
1997; Coccia, 2014b; 2016a, 2016b)6. These vital goals can be supported by disruptive innova-
tions that are highly directional and aimed at solving specific problems. The R&D process that 
leads firms in drug discovery industry to solutions of unsolved problems is governed by trial 
and error (cf., Wagner and Rosen, 2014). Simon (1962, p. 472, original emphasis) claimed that:  
 
The more difficult and novel the problem, the greater is likely to be the amount of trial and er-
ror required to find a solution. At the same time, the trial and error is not completely random 
or blind; it is, in fact, rather highly selective . . . . to see whether they represent progress to-
ward the goal. Indications of progress spur further search in the same direction; lack of pro-
gress signals the abandonment of a line of search. Problem solving requires selective trial and 
error. 
 
The central contribution of this work is an approach that integrates current frameworks in 
management of technology to clarify the sources of disruptive innovations (Dosi, 1988; 
O’Reilly III and Tushman, 2004; 2008; Cooper 1990). As a matter of fact, the theoretical 
framework of problem-driven innovation of this study have the potential to be generalized for 
explaining a basic source of disruptive technologies in several industries. In fact, technical com-
petence and problem-solving activity are crucial factors for developing several innovations 
since they translate environmental and organizational inputs into valuable new products and 
processes (cf. Atuahene-Gima and Wei, 2011, pp. 81-82; cf., Van de Ven et al., 2008). Other 
studies can support the thesis presented in this paper. Ruiz et al. (2012, p. 385ff) argue that new 
product development depends on accurately identifying problems across consumers and the 
“problem solving cycle” is a key activity of prototype-driven problem solving in heating prod-
ucts using information of users (Bogers and Horst, 2014, p. 744). Restuccia et al. (2016) ana-
lyze the industrial equipment and supply sectors and show that the concept of product-related 
problems is vital factor for new product development and based on the role of distributors that 
can support the innovation during the product life-cycle management. Critical problem-solving 
activity is also present in the semiconductor industry and it is associated with the main variable 
of speed because in this specific industry, expeditious problem solving is an important perfor-
mance goal to support technological innovations with short market life cycles (Appleyard et al., 
2006). Macher and Mowery (2003), in semiconductor manufacturing, also find that allocating 
engineering resources to problem-solving activities, associated with information technology and 
schedule production, influences new process technologies and manufacturing performance.  
In general, problem-solving competence is an important factor in firms to develop and sus-
tain disruptive innovations. The approach of problem-driven innovation here seems to be a 
comprehensive framework with the potential of explaining one of the general sources of disrup-
tive technologies for competitive advantage of firms over time and space. In particular, an effi-
cient innovation management depends on the ability to speed up the activities of solving com-
plex problems in the presence of environmental turbulence (Atuahene-Gima and Wei, 2011).  
Another finding of this study is that the emergence of disruptive innovations in drug discov-
ery industry need a R&D organization more and more based on a division of scientific labour 
(cf. ‘division of innovative labour’ by Arora and Gambardella 1995). This strategic change of 
R&D labs determines the shifts of the locus of innovations from individual firms (in-house 
R&D) to a R&D network (based on internal/ external source of innovation) by strategic allianc-
es and scientific collaborations across firms to support path-breaking drugs. Network R&D or-
ganizations reinforce the dynamic and sustaining capabilities7 of in-house R&D process by ex-
ternal sources of innovation (partnerships and strategic alliances with public and private labora-
                                                     
6 For organizational behaviour of public research labs see Coccia 2001, 2008, 2009a, 2009b; Coccia et al., 
2015; Coccia and Cadario, 2014; Coccia and Rolfo, 2007, 2010.  
7 Cf., Jenkins (2010); Paruchuri and Eisenman (2012).  
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tories operating in biotechnology and nanotechnology). In fact, Hage (2011, 53ff) shows that 
the growth in knowledge and convergence of research fields lead to a differentiation of research 
organizations and R&D networks to accelerate drug discovery processes. Overall, then, sources 
of disruptive innovations, in drug discovery industry, have benefits from linked R&D organiza-
tions that reinforce the cross-fertilization of technological capabilities by the collective and cu-
mulative learning, by the generation of multiplicity of stimuli and by the adoption of different 
and complementary approaches (cf., Gherardi, 1999).  
However, innovations in medicine and other research fields are due to manifold fac-
tors. The learning process between clinical research and clinical practice is also a vital factor 
that supports in this and other research fields the accumulation and advancement of technical 
knowledge (cf. Gelijns and Rosenberg, 1995, p. 4ff; Gershon, 1998). In fact, the Development 
phase in medicine, with learning processes based on the interplay between clinical research and 
clinical practice, supports radical innovations and their improvement (incremental innovation, 
Gelijns and Rosenberg, 1995). Another factor for the development of innovation is the dynamic 
capability: “the firm’s ability to integrate, build, and reconfigure internal and external compe-
tences to address rapidly changing environments” (Teece et al., 1997, p. 516; Helfat et al., 
2007, p. 4; Coccia, 2014b). Innovation and its development are also due to organizational learn-
ing, which is a fundamental strategic process for competitive advantage of firms (Vera and 
Crossan, 2004). Moreover, managers with strategic leadership within firms play a vital for in-
novation processes because they inspire others with their vision, create excitement in groups 
and provide incentives for achieving goals in competitive environments (Bass and Avolio, 
1990). The evolution of new technology can be also due to “inventive analogical transfer” from 
experience and solutions of consequential problems in one knowledge area—source domain—to 
other fields—target domains (Kalogerakis et al., 2010, p. 418).  
6. CONCLUDING OBSERVATIONS 
The high mortality rate of lung cancer is a major unsolved problem and is a main impetus for 
firms in drug discovery industry -characterized by technological and market dynamisms- to de-
velop disruptive technologies of anticancer drugs. On the basis of the argument presented in this 
paper, based on a case study research, we can therefore conclude that one of principal sources of 
disruptive innovations is due to a coevolution of consequential problems and related solutions in 
competitive markets, ceteris paribus. As a matter of fact, the inductive analysis here shows that 
disruptive innovations of anticancer drugs embody the development of specific technological 
pathways in a circumscribed problem-solving and learning activity (cf., Dosi, 1988). This pro-
cess, leading to disruptive innovations, is based on specific dynamic capabilities of firms and 
previous technological solutions that generate learning processes, a vital cumulative change and 
path dependence in innovative industries (cf., Garud and Karnøe, 2001; Garud et al., 2010; 
Teece et al., 1997). These findings seem to be also confirmed by other studies, such as Coccia 
and Wang (2015, p. 155ff) show that: “the sharp increase of several technological trajectories of 
anticancer drugs applied by nanotechnology seems to be driven by high rates of mortality of 
some types of cancers (e.g., pancreatic and brain) in order to find more effective anticancer 
therapies that increase the progression-free survival of patients”. These “technological trajecto-
ries mortality driven” are problem-driven by high mortality in pancreatic and brain cancer. In 
short, relevant and consequential problems seem to be a main and general driving force for dis-
ruptive innovations in pharmaceuticals and other industries. In fact, Roche (2015), a multina-
tional health-care company, claims that the research process in medicine has to find: “innovative 
solutions for serious, currently unsolved medical problems”. In short, firms in the drug-
discovery industry have a main incentive to find innovative solutions with new products for un-
solved problems in order to achieve the goal of a (temporary) profit monopoly. The hypothesis 
of problem-driven innovation can explain one of driving forces of several innovations in drug 
discovery industry and has also the potential to explain one of the general sources of technolog-
ical paradigms and trajectories that support the technological, industrial and economic change. 
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Moreover, case study research here shows that R&D management has, in drug discovery indus-
try, more and more a division of scientific labour directed to support solutions of relevant prob-
lems that may develop disruptive technologies. 
In particular,  
 
(1)  The conceptual framework here assigns a central role to relevant problems and their 
solution to explain the origin of disruptive technologies that sustain the industrial and 
corporate change;   
(2)  The conceptual framework also shows that disruptive technologies are mainly generat-
ed by incumbent firms in sectors at high intensity of R&D investments. However, 
small (entrant) firms can generate radical innovations but they have to cope with high 
economic resources needed for developing the innovations in drug discovery industry 
(cf., Caner et al., 2016). This financial issue explains the strategic alliances and part-
nerships between incumbent and entrant firms to develop disruptive and new technol-
ogies. A main example is represented by the global collaboration between AstraZeneca 
and Amgen (a leader in biotechnology) to co-develop and commercialize five mono-
clonal antibodies from Amgen’s clinical portfolio. The collaboration with Amgen is 
designed to share risk and leverage each partner’s functional and geographic strengths. 
This collaboration improves the expertise of AstraZeneca in respiratory and gastroin-
testinal diseases, whereas Amgen improves commercial experience in rheumatologic 
and dermatologic diseases. This collaboration marks a new phase in biopharmaceutical 
business development of innovations (AstraZeneca, 2015). Moreover, the need of high 
economic resources to compete in this drug discovery industry -with high intensity of 
R&D investments- induces small firms, such as Clovis oncology, to enter in the stock 
exchange to gather financial resources directed to R&D of several innovative products 
in the pipeline.    
(3)  Finally, the conceptual framework here also shows that the problem-solving activity to 
generate disruptive innovations in anticancer treatments is based on network R&D or-
ganizations for a division of scientific labor directed to reinforcing the integrative ca-
pabilities and collective learning between internal and external sources of innovation. 
 
Overall, then, the conceptual framework here, substantiated in drug discovery industry, has 
several components of generalization that could easily be extended to explain the source of dis-
ruptive technologies across several industries. This study offers important insights to knowledge 
in these research fields, but the study's findings need to be considered in light of their limita-
tions. In fact, disruptive technologies investigated in this study are a problematic topic due to 
the diversity across industries and sectors. However, disruptive innovations in this and other in-
dustries are due to manifold factors and these results are of course tentative because we know 
that other things are often not equal over time and space. Especially limiting is the fact that our 
approach to analysis did not permit some intervening variables that may have been useful in 
providing a deeper and richer explanation of these phenomena of interests. Hence, much work 
remains if we are to understand in more depth the reasons for and the implications of disruptive 
technologies. To conclude, this study provides a preliminary analysis of how firms generate 
specific disruptive innovations in the presence of technological and market dynamism. More fi-
ne-grained studies will be useful in future, ones that can more easily examine other complex 
predictors of disruptive technologies. Most of the focus here is on a case study research of new 
anticancer treatments, clearly important but not sufficient for broader understanding of the com-
plex sources of disruptive technologies. In fact, Wright (1997, p. 1562) properly claims: “In the 
world of technological change, bounded rationality is the rule”.  
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